Azithromycin

Generic Name: Azithromycin

Brand Names: Azasite, Zithromax, Zmax

Drug Type: Small Molecule

Chemical Formula: C_₃₈H_₇₂N_₂O_₁₂

CAS Number: 83905-01-5

Unique Ingredient Identifier: J2KLZ20U1M

Background: Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .
...

Indication: Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin .
...

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Acute bacterial exacerbation of COPD caused by Haemophilus Influenza Infections, Moraxella Catarrhalis Infection, Streptococcus Pneumoniae Infections, Bacterial Conjunctivitis, Bacterial Sinusitis, Cervicitis, Chancroid, Community Acquired Pneumonia (CAP), Genital Ulcer Disease (GUD), Pelvic Inflammatory Disease (PID), Pharyngitis, Streptococcal Pharyngitis, Tonsillitis bacterial, Tonsillitis streptococcal, Traveler's Diarrhea, Uncomplicated Skin and Skin Structure Infections, Urethritis

Associated Therapies: -

Clinical Trials

Azithromycin for Meningococcal Carriage

Phase 2

Recruiting

Conditions: Meningococcal Infections

Interventions: Drug: Azithromycin

First Posted Date: 2024-10-01

Last Posted Date: 2024-11-14

Lead Sponsor: Emory University

Target Recruit Count: 1120

Registration Number: NCT06618534

Locations: 🇺🇸
Hope Clinic of the Emory Vaccine Center, Decatur, Georgia, United States

Clinical Observations of Pain and Pruritus Induced by Exposure to Allergic Contact Dermatitis Caused by Macrolides

Not yet recruiting

Conditions: Dermatitis, Allergic Contact

Interventions: Drug: Erythromycin
Other: physiological saline
Drug: Azithromycin

First Posted Date: 2024-08-27

Last Posted Date: 2024-08-27

Lead Sponsor: Affiliated Hospital of Nantong University

Target Recruit Count: 30

Registration Number: NCT06574204

Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0

Phase 2

Recruiting

Conditions: Obesity in Pregnancy
Labor Complication

Interventions: Drug: Placebo
Drug: Azithromycin

First Posted Date: 2024-07-05

Last Posted Date: 2024-10-24

Lead Sponsor: University of Oklahoma

Target Recruit Count: 787

Registration Number: NCT06488781

Locations: 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol]

Not Applicable

Not yet recruiting

Conditions: Preterm Birth

Interventions: Drug: Erythromycin
Drug: Amoxicillin and Erythromycin
Drug: Azithromycin

First Posted Date: 2024-06-17

Last Posted Date: 2024-06-17

Lead Sponsor: University of Melbourne

Target Recruit Count: 100000

Registration Number: NCT06461429

Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)

Phase 4

Recruiting

Conditions: Pregnancy, High Risk
Preterm Birth
Preterm Premature Rupture of Membrane

Interventions: Drug: Ceftriaxone 1000 MG
Drug: Ampicillin 2 GM Injection
Drug: Amoxicillin 250 MG
Drug: Clarithromycin 500mg
Drug: Metronidazole 500 mg
Drug: Azithromycin
Drug: Erythromycin

First Posted Date: 2024-05-02

Last Posted Date: 2024-07-29

Lead Sponsor: Ohio State University

Target Recruit Count: 56

Registration Number: NCT06396078

Locations: 🇺🇸
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus, Ohio, United States

Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth

Phase 4

Not yet recruiting

Conditions: Bacterial Vaginosis
Vaginal Dysbiosis
Premature Delivery

Interventions: Diagnostic Test: Vaginal flora abnormalities screening and quantification using molecular biology technique
Other: Usual Care
Drug: Azithromycine
Drug: Ceftriaxone
Drug: Metronidazole
Drug: Clotrimazole, Vaginal

First Posted Date: 2024-04-05

Last Posted Date: 2024-04-05

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 1292

Registration Number: NCT06349122

Azithromycin Reduction to Reach Elimination of Trachoma B

Phase 4

Not yet recruiting

Conditions: Trachoma

Interventions: Drug: Azithromycin

First Posted Date: 2024-03-04

Last Posted Date: 2024-05-08

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 100000

Registration Number: NCT06289647

Locations: 🇨🇩
University of California, San Francisco, Kindu, Maniema, Congo, The Democratic Republic of the

Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes

Phase 3

Recruiting

Conditions: Premature Rupture of Membrane

Interventions: Drug: Erythromycin
Drug: Azithromycin

First Posted Date: 2024-02-23

Last Posted Date: 2024-06-04

Lead Sponsor: Inova Fairfax Hospital

Target Recruit Count: 140

Registration Number: NCT06273891

Locations: 🇺🇸
Inova Fairfax Medical Campus, Falls Church, Virginia, United States
🇺🇸
Eastern Viriginia Medical School, Norfolk, Virginia, United States